| dc.contributor |
Fakultas Kedokteran |
|
| dc.creator |
Marwarni, Fadhilah |
|
| dc.creator |
Rachmi, Ami |
|
| dc.creator |
Yuniarti, Lelly |
|
| dc.date |
2021-01-24 |
|
| dc.date.accessioned |
2021-03-15T04:12:22Z |
|
| dc.date.available |
2021-03-15T04:12:22Z |
|
| dc.identifier |
http://karyailmiah.unisba.ac.id/index.php/dokter/article/view/26748 |
|
| dc.identifier |
10.29313/kedokteran.v7i1.26748 |
|
| dc.identifier.uri |
http://hdl.handle.net/123456789/29748 |
|
| dc.description |
Abstract. Tuberculosis is a infectious disease caused by Mycobacterium tuberculosis. This disease attacks the lungs (pulmonary tuberculosis) and can affect other parts of the body (extrapulmonary tuberculosis). The BCG vaccine can prevent the incidence of severe TB in children and the risk of death. The effectiveness of the BCG vaccine decreases with time and cannot protect adults from pulmonary TB so a BCG booster vaccine using recombinant vaccine is needed. This scoping review aims to explore and analyze systematically articles related to the effectiveness of administering revaccines or BCG booster vaccines or their recombinants in increasing immunity against Mycobacterium tuberculosis. This research is a Scoping Review, by searching for articles from PubMed, Springer Link, and Science Direct databases. There were 280 articles that matched the inclusion criteria and 275 articles that were included in the exclusion criteria. The PICOS criteria in this study were Population (people who had been given BCG vaccine), Intervention (vaccine booster BCG or its recombinant), Comparison (people who were not given thevaccine booster), Outcome (immunity to Mycobacterium tuberculosis), Study (Randomized Control Trial). This research was conducted in the period November-December 2020. The articles that reviewed were five articles. The analysis showed vaccine a booster in the form of a recombinant vaccine and a recombinant vaccine together with an adjuvant shown to be safe, well tolerated and immunogenic thus considered protective against M. tuberculosis. The conclusion: the administration of the Bacile Calmette Guerin (BCG) booster vaccine or its recombinant is effective in increasing the immune system against Mycobacterium Tuberculosis, the types of recombinant vaccines that are effective are MVA85A, AERAS-402, H4: IC31, H56: IC31.Keywords: BCG vaccine, BCG vaccine booster, efficacy tuberculosisAbstrak. Tuberkulosis adalah penyakit menular yang disebabkan oleh Mycobacterium tuberculosis. Penyakit ini menyerang paru (tuberkulosis paru) dan dapat menyerang bagian tubuh lain (tuberkulosis ekstrapulmonal). Vaksin BCG dapat mencegah kejadian TB yang berat pada anak dan risiko kematian. Efektivitas vaksin BCG menurun bersamaan dengan waktu dan tidak dapat memproteksi orang dewasa dari TB paru sehingga dibutuhkan vaksin booster BCG menggunakan vaksin rekombinan. Scoping review ini bertujuan mengeksplorasi dan menganalisis secara sistematis artikel yang terkait dengan efektivitas pemberian revaksin atau vaksin booster BCG atau rekombinannya pada peningkatan imunitas terhadap Mycobacterium tuberculosis. Penelitian ini merupakan Scoping Review dengan mencari artikel dari database PubMed, Springer Link, dan Science Direct. Artikel yang sesuai dengan kriteria inklusi sebanyak 280 artikel dan yang termasuk dalam kriteria eksklusi sebanyak 275 artikel. Kriteria PICOS dalam penelitian ini adalah Population (orang yang sudah diberikan vaksin BCG), Intervention (pemberian vaksin booster BCG atau rekombinannya), Comparison (orang yang tidak diberikan vaksin booster), Outcome (imunitas terhadap Mycobacterium tuberculosis), Study (Randomized Control Trial). Penelitian ini dilakukan pada periode November-Desember 2020. Artikel yang di-review sebanyak lima artikel. Hasil analisis menunjukkan vaksin booster berupa vaksin rekombinan maupun vaksin rekombinan bersama adjuvan terbukti aman, dapat ditoleransi dengan baik, dan bersifat imunogenik sehingga dianggap protektif terhadap M. tuberculosis. Kesimpulan: pemberian vaksin booster Bacile Calmette Guerin (BCG) atau rekombinannya efektif dalam meningkatkan sistem imun terhadap Mycobacterium tuberculosis, jenis vaksin rekombinan yang efektif adalah MVA85A, AERAS-402, H4:IC31, H56:IC31.Kata kunci: BCG vaksin, BCG vaksin booster, efikasi tuberkulosis |
|
| dc.language |
id |
|
| dc.publisher |
Universitas Islam Bandung |
|
| dc.rights |
Copyright (c) 2021 Prosiding Pendidikan Dokter |
|
| dc.source |
Prosiding Pendidikan Dokter; Vol 7, No 1, Prosiding Pedidikan Kedokteran (Februari, 2021)0 |
|
| dc.source |
Prosiding Pendidikan Dokter; Vol 7, No 1, Prosiding Pedidikan Kedokteran (Februari, 2021)0 |
|
| dc.source |
2460-657X |
|
| dc.source |
10.29313/kedokteran.v7i1 |
|
| dc.subject |
Pendidikan Dokter |
|
| dc.subject |
BCG vaksin, BCG vaksin booster, efikasi tuberkulosis |
|
| dc.title |
Scoping Review: Efektivitas Pemberian Vaksin Booster Bacille Calmette Guerin (BCG) atau Rekombinannya pada Peningkatan Sistem Imun terhadap Mycobacterium Tuberculosis |
|
| dc.type |
info:eu-repo/semantics/article |
|
| dc.type |
info:eu-repo/semantics/publishedVersion |
|
| dc.type |
Peer-reviewed Article |
|
| dc.type |
Kuantitatif |
|